244 related articles for article (PubMed ID: 19883868)
1. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009.
Adam D
Vaccine; 2009 Nov; 27(50):7133-7. PubMed ID: 19883868
[TBL] [Abstract][Full Text] [Related]
2. 27th Annual Meeting of the European Society for Pediatric Infectious Disease.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2009 Sep; 8(9):1143-9. PubMed ID: 19722887
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
Ray GT
Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
[TBL] [Abstract][Full Text] [Related]
4. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
Rose M; Zielen S
Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
[TBL] [Abstract][Full Text] [Related]
5. Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance.
Vergison A; Hanquet G
Pediatr Infect Dis J; 2012 Apr; 31(4):400-3. PubMed ID: 22418653
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
7. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine.
Long SS
Clin Infect Dis; 2005 Jul; 41(1):30-4. PubMed ID: 15937759
[No Abstract] [Full Text] [Related]
8. Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine.
Obando I; Arroyo LA; Sánchez-Tatay D; Tarragó D; Moreno D; Hausdorff WP; Brueggemann AB
Clin Microbiol Infect; 2007 Mar; 13(3):347-8. PubMed ID: 17391398
[No Abstract] [Full Text] [Related]
9. From global to regional: the importance of pneumococcal disease in Latin America.
de Quadros CA
Vaccine; 2009 Aug; 27 Suppl 3():C29-32. PubMed ID: 19540025
[TBL] [Abstract][Full Text] [Related]
10. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
[TBL] [Abstract][Full Text] [Related]
11. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
12. Understanding the link between pneumococcal serotypes and invasive disease.
Soley C; Arguedas A
Vaccine; 2009 Aug; 27 Suppl 3():C19-21. PubMed ID: 19535183
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
[TBL] [Abstract][Full Text] [Related]
14. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines.
von Kries R; Siedler A; Schmitt HJ; Reinert RR
Clin Infect Dis; 2000 Aug; 31(2):482-7. PubMed ID: 10987709
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
Toltzis P; Jacobs MR
Infect Dis Clin North Am; 2005 Sep; 19(3):629-45. PubMed ID: 16102653
[TBL] [Abstract][Full Text] [Related]
16. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).
Beutels P; Thiry N; Van Damme P
Vaccine; 2007 Feb; 25(8):1355-67. PubMed ID: 17208339
[TBL] [Abstract][Full Text] [Related]
17. Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era.
Pichichero ME; Casey JR
Pediatr Infect Dis J; 2007 Oct; 26(10 Suppl):S12-6. PubMed ID: 18049375
[TBL] [Abstract][Full Text] [Related]
18. Increasing focus on local epidemiology demonstrates potential value of pneumococcal conjugate vaccines in Middle East and North Africa Region.
Pelton SI
Vaccine; 2012 Dec; 30 Suppl 6():G1. PubMed ID: 23228351
[No Abstract] [Full Text] [Related]
19. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe.
Reinert RR; Paradiso P; Fritzell B
Expert Rev Vaccines; 2010 Mar; 9(3):229-36. PubMed ID: 20218848
[No Abstract] [Full Text] [Related]
20. Vaccine policy decisions: tension between science, cost-effectiveness and consensus?
Zimmerman RK; Jackson RE
Am Fam Physician; 2001 May; 63(10):1919, 1923. PubMed ID: 11388708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
